Clinical Trials Browser

Nasopharyngeal Carcinoma

Glioblastoma

Turcot syndrome, Microsatellite Instability

Colonic Neoplasms

Carcinoma, Merkel Cell

Uveal Melanoma

Carcinoma, Basal Cell

Advanced Biliary Tract Cancer(BTC)

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Microsatellite Unstable Colorectal Cancer

Carcinoma, Non-Small-Cell Lung

Tertiary Lymphoid Structures, Neoplasm Metastasis, Neoplasms, Sarcoma

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Lymphoma, Multiple Myeloma

Stomach Neoplasms

Advanced Gastric Cancer

Advanced Cancer

Advanced Cancer

Stomach Neoplasms

Clinical Trials

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

NICHE

Neo IRENIE

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

NEON

NOBLE

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

CheckMate142

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

CONGRATS

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

NEOpredict

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

IMAGINE

FRACTION-GC

FRACTION-RCC

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

FRACTION-Lung

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma